Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.
Ayalew Tefferi, MD
Advertisement
Articles by Ayalew Tefferi, MD
Advertisement
Latest Updated Articles
The Outlook for JAK Inhibitors in MyelofibrosisPublished: January 2nd 2014 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
